Verastem Oncology Launches LGSOC Resource Guide to Support Rare Cancer Patients

Event summary

  • Verastem Oncology, STAAR Foundation, and Not These Ovaries launched the LGSOC Resource Guide on World Ovarian Cancer Day (May 8, 2026).
  • The guide consolidates educational materials and community resources for low-grade serous ovarian cancer (LGSOC) patients, caregivers, and advocates.
  • LGSOC is a rare form of ovarian cancer affecting 6,000-8,000 women in the U.S. and 80,000 worldwide, with distinct treatment needs.
  • The guide follows Verastem's FDA-approved treatment for KRAS-mutated recurrent LGSOC, developed after an Externally-led Patient-Focused Drug Development (EL-PFDD) meeting in 2023.

The big picture

The launch of the LGSOC Resource Guide underscores Verastem Oncology's strategic focus on rare cancers with unmet medical needs. By partnering with patient advocacy groups, Verastem aims to bridge gaps in diagnosis and treatment, reinforcing its position in the RAS/MAPK pathway-driven cancer space. This initiative aligns with broader industry trends toward patient-centric drug development and regulatory collaboration for rare diseases.

What we're watching

Regulatory Engagement
How Verastem's continued collaboration with the FDA will shape future LGSOC treatment approvals.
Patient Advocacy Impact
Whether the LGSOC Resource Guide can improve diagnosis and treatment outcomes for rare cancer patients.
Treatment Innovation
The pace at which Verastem can develop new therapies tailored to LGSOC's unique biology.

Related topics

Oncology